



Evolut Clinical Guideline 3255 for Votrient™ (pazopanib)

Guideline Number: Evolut_CG_3255	<u>Applicable Codes</u>	
<i>"Evolut" refers to Evolut Health LLC and Evolut Specialty Services, Inc. © 2012 - 2026 Evolut. All rights Reserved.</i>		
Original Date: January 2012	Last Revised Date: January 2026	Implementation Date: January 2026

TABLE OF CONTENTS

STATEMENT	2
PURPOSE	2
INDICATIONS	2
RENAL CELL CARCINOMA (RCC).....	2
SOFT TISSUE SARCOMA.....	3
CONTRAINDICATIONS/WARNINGS	3
EXCLUSION CRITERIA	3
CODING AND STANDARDS	4
CODES.....	4
APPLICABLE LINES OF BUSINESS	4
POLICY HISTORY	4
LEGAL AND COMPLIANCE	4
GUIDELINE APPROVAL	4
<i>Committee</i>	4
DISCLAIMER	5
REFERENCES	5

STATEMENT

Purpose

To define and describe the accepted indications for Votrient (pazopanib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

INDICATIONS

Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

Renal Cell Carcinoma (RCC)

- Votrient (pazopanib) may be used in adult members with recurrent/metastatic renal cell carcinoma for ANY of the following clinical settings:
 - As a single agent for first line therapy and IMDC Criteria Favorable Risk Disease OR
 - As a single agent for subsequent line therapy, regardless of IMDC Risk category.
- IMDC criteria: Please see table below (Reference below)

CRITERIA= Assign 1 point for each	RISK CATEGORIES= RISK SCORE
Time to systemic treatment less than 1 year from diagnosis	Favorable Risk = 0
Performance Status < 80% Karnofsky Scale	Intermediate Risk = 1-2
Hemoglobin < LLN; <12 g/dL	Poor Risk= 3-6
Calcium > ULN; > 12 mg/dL	
Neutrophils > ULN	
Platelets > ULN	

Soft Tissue Sarcoma

- Votrient (pazopanib) may be used as a single agent in adult members as palliative therapy for recurrent or metastatic soft tissue sarcoma as subsequent line therapy.

CONTRAINDICATIONS/WARNINGS

- US Boxed Warning
 - Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended.

EXCLUSION CRITERIA

- The member has stage I-III RCC, soft tissue sarcoma, or gastrointestinal stromal tumors.
- Votrient (pazopanib) is being used concurrently with other anticancer therapy.
- Member has disease progression while taking Votrient (pazopanib).
- Dosing exceeds single dose limit of Votrient (pazopanib) 800 mg.
- Treatment exceeds the maximum limit of 120 (200 mg) tablets/month.
- Investigational use of Votrient (pazopanib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definition of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of < 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 - Whether the experimental design, in light of the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
 - That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
 - That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining

accepted uses of drugs.

CODING AND STANDARDS

Codes

- J8999 - pazopanib

Applicable Lines of Business

<input type="checkbox"/>	CHIP (Children’s Health Insurance Program)
<input checked="" type="checkbox"/>	Commercial
<input checked="" type="checkbox"/>	Exchange/Marketplace
<input checked="" type="checkbox"/>	Medicaid
<input type="checkbox"/>	Medicare Advantage

POLICY HISTORY

Date	Summary
January 2026	<ul style="list-style-type: none"> • Converted to new Evolent guideline template • This guideline replaces UM ONC_1195 Votrient (pazopanib) • Updated indication section • Updated exclusion criteria • Updated references
January 2025	<ul style="list-style-type: none"> • Added Evolent disclaimer language • Added Coding Information section with HCPCS code

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

REFERENCES

1. Sternberg CN, et al. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. *Oncology*. 2014;87(6):342-50. doi: 10.1159/000366227.
2. Sternberg CN, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. *Eur J Cancer*. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010.
3. Kawai A, et al. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. *Jpn J Clin Oncol*. 2016 Mar;46(3):248-53. doi: 10.1093/jjco/hyv184.
4. Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol*. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809.
5. Votrient prescribing information. Novartis Pharmaceuticals Corporation. East Hanover, NJ 2024.
6. Clinical Pharmacology Elsevier Gold Standard 2026.
7. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2026.
8. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2026.
9. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2026.
10. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
11. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
12. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.